Dr. Ryan D. Cassaday

Claim this profile

Fred Hutchinson Cancer Research Center

Studies Burkitt Lymphoma
Studies Acute Lymphoblastic Leukemia
3 reported clinical trials
9 drugs studied

Area of expertise

1

Burkitt Lymphoma

Ryan D. Cassaday has run 2 trials for Burkitt Lymphoma. Some of their research focus areas include:

CD19 positive
Ph negative
2

Acute Lymphoblastic Leukemia

Ryan D. Cassaday has run 2 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:

CD19 positive
Ph negative

Affiliated Hospitals

Image of trial facility.

Fred Hutchinson Cancer Research Center

Image of trial facility.

University Of Washington Medical Center - Montlake

Clinical Trials Ryan D. Cassaday is currently running

Image of trial facility.

Chemotherapy + Targeted Therapy

for Acute Lymphoblastic Leukemia

This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the treatment of patients with newly diagnosed Philadelphia chromosome negative (Ph-) B acute lymphoblastic leukemia (B-ALL). Chemotherapy drugs, such as those in EPOCH+/-R, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tafasitamab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Adding tafasitamab to the DA-EPOCH+/-R regimen may work better than DA-EPOCH+/-R alone in treating newly diagnosed Ph- B-ALL.

Recruiting

2 awards

Phase 2

Image of trial facility.

OBI-3424

for T-Cell Acute Lymphoblastic Leukemia

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

Recruiting

1 award

Phase 1 & 2

19 criteria

More about Ryan D. Cassaday

Clinical Trial Related

2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Ryan D. Cassaday has experience with

  • Doxorubicin
  • Prednisone
  • Asparaginase Erwinia Chrysanthemi
  • Rituximab
  • Cyclophosphamide
  • Etoposide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ryan D. Cassaday specialize in?

Is Ryan D. Cassaday currently recruiting for clinical trials?

Are there any treatments that Ryan D. Cassaday has studied deeply?

What is the best way to schedule an appointment with Ryan D. Cassaday?

What is the office address of Ryan D. Cassaday?

Is there any support for travel costs?